Inogen (INGN) has seen the share price implosion continue in recent weeks and months, while this was of the market's darlings last year. While momentum seen last year was clearly not sustainable, the question is if the situation has reversed to the other side.
The company has seen solid sales momentum in recent years yet has failed to deliver on operating leverage. The market potential is clear, but so is competition, pricing pressure, and headwinds in reimbursement policies. In January, I reviewed the situation in greater detail as I saw appeal improving, yet